Urine Cell-Free DNA integrity as a marker for early bladder cancer diagnosis: Preliminary data

Abstract Objectives Urine cell-free (UCF) DNA has recently been proposed as a potential marker for early bladder cancer diagnosis. It is known that normal apoptotic cells produce highly fragmented DNA while cancer cells release longer DNA. Therefore, we verified the potential role of UCF DNA integri...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Urologic oncology 2013-11, Vol.31 (8), p.1744-1750
Hauptverfasser: Casadio, Valentina, B.S, Calistri, Daniele, Ph.D, Tebaldi, Michela, B.S, Bravaccini, Sara, B.S, Gunelli, Roberta, M.D, Martorana, Giuseppe, M.D, Bertaccini, Alessandro, M.D, Serra, Luigi, M.D, Scarpi, Emanuela, M.S, Amadori, Dino, M.D, Silvestrini, Rosella, Ph.D, Zoli, Wainer, Ph.D
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1750
container_issue 8
container_start_page 1744
container_title Urologic oncology
container_volume 31
creator Casadio, Valentina, B.S
Calistri, Daniele, Ph.D
Tebaldi, Michela, B.S
Bravaccini, Sara, B.S
Gunelli, Roberta, M.D
Martorana, Giuseppe, M.D
Bertaccini, Alessandro, M.D
Serra, Luigi, M.D
Scarpi, Emanuela, M.S
Amadori, Dino, M.D
Silvestrini, Rosella, Ph.D
Zoli, Wainer, Ph.D
description Abstract Objectives Urine cell-free (UCF) DNA has recently been proposed as a potential marker for early bladder cancer diagnosis. It is known that normal apoptotic cells produce highly fragmented DNA while cancer cells release longer DNA. Therefore, we verified the potential role of UCF DNA integrity in early bladder cancer diagnosis. Materials and methods UCF DNA was isolated from 51 bladder cancer patients, 46 symptomatic patients, and 32 healthy volunteers. To verify UCF DNA integrity, sequences longer than 250 bp, c-Myc , BCAS1 , and HER2 , were quantified by real time PCR. Results At the best cutoff value of 0.1 ng/μl, UCF DNA integrity analysis showed a sensitivity of 0.73 (95% CI 0.61–0.85), and a specificity of 0.84 (95% CI 0.71–0.97) in healthy individuals and 0.83 (95% CI 0.72–0.94) in symptomatic patients. Receiver operating characteristic (ROC) curve analysis revealed an area under the curve of 0.834 (95% CI 0.739–0.930) for healthy individuals and 0.796 (95% CI 0.707–0.885) for symptomatic patients. Conclusions These preliminary data suggest that UCF DNA integrity is a potentially good marker for early noninvasive diagnosis of bladder cancer. Its diagnostic performance does not seem to vary significantly, even in an “at risk” population of symptomatic individuals.
doi_str_mv 10.1016/j.urolonc.2012.07.013
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1450194353</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S1078143912002554</els_id><sourcerecordid>1450194353</sourcerecordid><originalsourceid>FETCH-LOGICAL-c430t-dca62e6638fc717174618178224f0f0f6d2f21b2bc993af6766e2795dd66b75e3</originalsourceid><addsrcrecordid>eNo9kcFu1DAQhiMEoqXwCCAfuST12I6dcECqtpRWqigS9Irl2JPKW69T7KRS3h6vdqnmMKPRP2P_31TVR6ANUJDn22ZJU5iibRgF1lDVUOCvqlPoFK-Z6OXrUlPV1SB4f1K9y3lLKYgO4G11wjgIUB0_rf7cJx-RbDCE-iohkssfF8THGR-Sn1diMjFkZ9IjJjJOiaBJYSVDMM6VjjXRluS8eYhT9vkL-Zkw-J2PJq3Emdm8r96MJmT8cMxn1f3Vt9-b6_r27vvN5uK2toLTuXbWSIZS8m60CkoICV35IGNipCWkYyODgQ2277kZpZISmepb56QcVIv8rPp82PuUpr8L5lnvfLbFlIk4LVmDaCn0gre8SNuD1KYp54Sjfkq-WFw1UL1Hq7f6iFbv0WqqdEFb5j4dn1iGHbqXqf8si-DrQYDF6LPHpG3w0VsTHnHFvJ2WFAsDDTqXpfrX_jr74wCjlLWt4P8AY62LNA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1450194353</pqid></control><display><type>article</type><title>Urine Cell-Free DNA integrity as a marker for early bladder cancer diagnosis: Preliminary data</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Casadio, Valentina, B.S ; Calistri, Daniele, Ph.D ; Tebaldi, Michela, B.S ; Bravaccini, Sara, B.S ; Gunelli, Roberta, M.D ; Martorana, Giuseppe, M.D ; Bertaccini, Alessandro, M.D ; Serra, Luigi, M.D ; Scarpi, Emanuela, M.S ; Amadori, Dino, M.D ; Silvestrini, Rosella, Ph.D ; Zoli, Wainer, Ph.D</creator><creatorcontrib>Casadio, Valentina, B.S ; Calistri, Daniele, Ph.D ; Tebaldi, Michela, B.S ; Bravaccini, Sara, B.S ; Gunelli, Roberta, M.D ; Martorana, Giuseppe, M.D ; Bertaccini, Alessandro, M.D ; Serra, Luigi, M.D ; Scarpi, Emanuela, M.S ; Amadori, Dino, M.D ; Silvestrini, Rosella, Ph.D ; Zoli, Wainer, Ph.D</creatorcontrib><description>Abstract Objectives Urine cell-free (UCF) DNA has recently been proposed as a potential marker for early bladder cancer diagnosis. It is known that normal apoptotic cells produce highly fragmented DNA while cancer cells release longer DNA. Therefore, we verified the potential role of UCF DNA integrity in early bladder cancer diagnosis. Materials and methods UCF DNA was isolated from 51 bladder cancer patients, 46 symptomatic patients, and 32 healthy volunteers. To verify UCF DNA integrity, sequences longer than 250 bp, c-Myc , BCAS1 , and HER2 , were quantified by real time PCR. Results At the best cutoff value of 0.1 ng/μl, UCF DNA integrity analysis showed a sensitivity of 0.73 (95% CI 0.61–0.85), and a specificity of 0.84 (95% CI 0.71–0.97) in healthy individuals and 0.83 (95% CI 0.72–0.94) in symptomatic patients. Receiver operating characteristic (ROC) curve analysis revealed an area under the curve of 0.834 (95% CI 0.739–0.930) for healthy individuals and 0.796 (95% CI 0.707–0.885) for symptomatic patients. Conclusions These preliminary data suggest that UCF DNA integrity is a potentially good marker for early noninvasive diagnosis of bladder cancer. Its diagnostic performance does not seem to vary significantly, even in an “at risk” population of symptomatic individuals.</description><identifier>ISSN: 1078-1439</identifier><identifier>EISSN: 1873-2496</identifier><identifier>DOI: 10.1016/j.urolonc.2012.07.013</identifier><identifier>PMID: 23141783</identifier><language>eng</language><publisher>United States</publisher><subject>Aged ; Biomarkers, Tumor - genetics ; Biomarkers, Tumor - urine ; DNA - genetics ; DNA - urine ; Early Detection of Cancer ; Female ; Humans ; Male ; Neoplasm Proteins - genetics ; Proto-Oncogene Proteins c-myc - genetics ; Real-Time Polymerase Chain Reaction ; Receptor, ErbB-2 - genetics ; Reference Values ; ROC Curve ; Spectrophotometry ; Urinary Bladder Neoplasms - diagnosis ; Urinary Bladder Neoplasms - genetics ; Urinary Bladder Neoplasms - urine ; Urology</subject><ispartof>Urologic oncology, 2013-11, Vol.31 (8), p.1744-1750</ispartof><rights>Elsevier Inc.</rights><rights>Copyright © 2013 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c430t-dca62e6638fc717174618178224f0f0f6d2f21b2bc993af6766e2795dd66b75e3</citedby><cites>FETCH-LOGICAL-c430t-dca62e6638fc717174618178224f0f0f6d2f21b2bc993af6766e2795dd66b75e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23141783$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Casadio, Valentina, B.S</creatorcontrib><creatorcontrib>Calistri, Daniele, Ph.D</creatorcontrib><creatorcontrib>Tebaldi, Michela, B.S</creatorcontrib><creatorcontrib>Bravaccini, Sara, B.S</creatorcontrib><creatorcontrib>Gunelli, Roberta, M.D</creatorcontrib><creatorcontrib>Martorana, Giuseppe, M.D</creatorcontrib><creatorcontrib>Bertaccini, Alessandro, M.D</creatorcontrib><creatorcontrib>Serra, Luigi, M.D</creatorcontrib><creatorcontrib>Scarpi, Emanuela, M.S</creatorcontrib><creatorcontrib>Amadori, Dino, M.D</creatorcontrib><creatorcontrib>Silvestrini, Rosella, Ph.D</creatorcontrib><creatorcontrib>Zoli, Wainer, Ph.D</creatorcontrib><title>Urine Cell-Free DNA integrity as a marker for early bladder cancer diagnosis: Preliminary data</title><title>Urologic oncology</title><addtitle>Urol Oncol</addtitle><description>Abstract Objectives Urine cell-free (UCF) DNA has recently been proposed as a potential marker for early bladder cancer diagnosis. It is known that normal apoptotic cells produce highly fragmented DNA while cancer cells release longer DNA. Therefore, we verified the potential role of UCF DNA integrity in early bladder cancer diagnosis. Materials and methods UCF DNA was isolated from 51 bladder cancer patients, 46 symptomatic patients, and 32 healthy volunteers. To verify UCF DNA integrity, sequences longer than 250 bp, c-Myc , BCAS1 , and HER2 , were quantified by real time PCR. Results At the best cutoff value of 0.1 ng/μl, UCF DNA integrity analysis showed a sensitivity of 0.73 (95% CI 0.61–0.85), and a specificity of 0.84 (95% CI 0.71–0.97) in healthy individuals and 0.83 (95% CI 0.72–0.94) in symptomatic patients. Receiver operating characteristic (ROC) curve analysis revealed an area under the curve of 0.834 (95% CI 0.739–0.930) for healthy individuals and 0.796 (95% CI 0.707–0.885) for symptomatic patients. Conclusions These preliminary data suggest that UCF DNA integrity is a potentially good marker for early noninvasive diagnosis of bladder cancer. Its diagnostic performance does not seem to vary significantly, even in an “at risk” population of symptomatic individuals.</description><subject>Aged</subject><subject>Biomarkers, Tumor - genetics</subject><subject>Biomarkers, Tumor - urine</subject><subject>DNA - genetics</subject><subject>DNA - urine</subject><subject>Early Detection of Cancer</subject><subject>Female</subject><subject>Humans</subject><subject>Male</subject><subject>Neoplasm Proteins - genetics</subject><subject>Proto-Oncogene Proteins c-myc - genetics</subject><subject>Real-Time Polymerase Chain Reaction</subject><subject>Receptor, ErbB-2 - genetics</subject><subject>Reference Values</subject><subject>ROC Curve</subject><subject>Spectrophotometry</subject><subject>Urinary Bladder Neoplasms - diagnosis</subject><subject>Urinary Bladder Neoplasms - genetics</subject><subject>Urinary Bladder Neoplasms - urine</subject><subject>Urology</subject><issn>1078-1439</issn><issn>1873-2496</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9kcFu1DAQhiMEoqXwCCAfuST12I6dcECqtpRWqigS9Irl2JPKW69T7KRS3h6vdqnmMKPRP2P_31TVR6ANUJDn22ZJU5iibRgF1lDVUOCvqlPoFK-Z6OXrUlPV1SB4f1K9y3lLKYgO4G11wjgIUB0_rf7cJx-RbDCE-iohkssfF8THGR-Sn1diMjFkZ9IjJjJOiaBJYSVDMM6VjjXRluS8eYhT9vkL-Zkw-J2PJq3Emdm8r96MJmT8cMxn1f3Vt9-b6_r27vvN5uK2toLTuXbWSIZS8m60CkoICV35IGNipCWkYyODgQ2277kZpZISmepb56QcVIv8rPp82PuUpr8L5lnvfLbFlIk4LVmDaCn0gre8SNuD1KYp54Sjfkq-WFw1UL1Hq7f6iFbv0WqqdEFb5j4dn1iGHbqXqf8si-DrQYDF6LPHpG3w0VsTHnHFvJ2WFAsDDTqXpfrX_jr74wCjlLWt4P8AY62LNA</recordid><startdate>20131101</startdate><enddate>20131101</enddate><creator>Casadio, Valentina, B.S</creator><creator>Calistri, Daniele, Ph.D</creator><creator>Tebaldi, Michela, B.S</creator><creator>Bravaccini, Sara, B.S</creator><creator>Gunelli, Roberta, M.D</creator><creator>Martorana, Giuseppe, M.D</creator><creator>Bertaccini, Alessandro, M.D</creator><creator>Serra, Luigi, M.D</creator><creator>Scarpi, Emanuela, M.S</creator><creator>Amadori, Dino, M.D</creator><creator>Silvestrini, Rosella, Ph.D</creator><creator>Zoli, Wainer, Ph.D</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20131101</creationdate><title>Urine Cell-Free DNA integrity as a marker for early bladder cancer diagnosis: Preliminary data</title><author>Casadio, Valentina, B.S ; Calistri, Daniele, Ph.D ; Tebaldi, Michela, B.S ; Bravaccini, Sara, B.S ; Gunelli, Roberta, M.D ; Martorana, Giuseppe, M.D ; Bertaccini, Alessandro, M.D ; Serra, Luigi, M.D ; Scarpi, Emanuela, M.S ; Amadori, Dino, M.D ; Silvestrini, Rosella, Ph.D ; Zoli, Wainer, Ph.D</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c430t-dca62e6638fc717174618178224f0f0f6d2f21b2bc993af6766e2795dd66b75e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Aged</topic><topic>Biomarkers, Tumor - genetics</topic><topic>Biomarkers, Tumor - urine</topic><topic>DNA - genetics</topic><topic>DNA - urine</topic><topic>Early Detection of Cancer</topic><topic>Female</topic><topic>Humans</topic><topic>Male</topic><topic>Neoplasm Proteins - genetics</topic><topic>Proto-Oncogene Proteins c-myc - genetics</topic><topic>Real-Time Polymerase Chain Reaction</topic><topic>Receptor, ErbB-2 - genetics</topic><topic>Reference Values</topic><topic>ROC Curve</topic><topic>Spectrophotometry</topic><topic>Urinary Bladder Neoplasms - diagnosis</topic><topic>Urinary Bladder Neoplasms - genetics</topic><topic>Urinary Bladder Neoplasms - urine</topic><topic>Urology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Casadio, Valentina, B.S</creatorcontrib><creatorcontrib>Calistri, Daniele, Ph.D</creatorcontrib><creatorcontrib>Tebaldi, Michela, B.S</creatorcontrib><creatorcontrib>Bravaccini, Sara, B.S</creatorcontrib><creatorcontrib>Gunelli, Roberta, M.D</creatorcontrib><creatorcontrib>Martorana, Giuseppe, M.D</creatorcontrib><creatorcontrib>Bertaccini, Alessandro, M.D</creatorcontrib><creatorcontrib>Serra, Luigi, M.D</creatorcontrib><creatorcontrib>Scarpi, Emanuela, M.S</creatorcontrib><creatorcontrib>Amadori, Dino, M.D</creatorcontrib><creatorcontrib>Silvestrini, Rosella, Ph.D</creatorcontrib><creatorcontrib>Zoli, Wainer, Ph.D</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Urologic oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Casadio, Valentina, B.S</au><au>Calistri, Daniele, Ph.D</au><au>Tebaldi, Michela, B.S</au><au>Bravaccini, Sara, B.S</au><au>Gunelli, Roberta, M.D</au><au>Martorana, Giuseppe, M.D</au><au>Bertaccini, Alessandro, M.D</au><au>Serra, Luigi, M.D</au><au>Scarpi, Emanuela, M.S</au><au>Amadori, Dino, M.D</au><au>Silvestrini, Rosella, Ph.D</au><au>Zoli, Wainer, Ph.D</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Urine Cell-Free DNA integrity as a marker for early bladder cancer diagnosis: Preliminary data</atitle><jtitle>Urologic oncology</jtitle><addtitle>Urol Oncol</addtitle><date>2013-11-01</date><risdate>2013</risdate><volume>31</volume><issue>8</issue><spage>1744</spage><epage>1750</epage><pages>1744-1750</pages><issn>1078-1439</issn><eissn>1873-2496</eissn><abstract>Abstract Objectives Urine cell-free (UCF) DNA has recently been proposed as a potential marker for early bladder cancer diagnosis. It is known that normal apoptotic cells produce highly fragmented DNA while cancer cells release longer DNA. Therefore, we verified the potential role of UCF DNA integrity in early bladder cancer diagnosis. Materials and methods UCF DNA was isolated from 51 bladder cancer patients, 46 symptomatic patients, and 32 healthy volunteers. To verify UCF DNA integrity, sequences longer than 250 bp, c-Myc , BCAS1 , and HER2 , were quantified by real time PCR. Results At the best cutoff value of 0.1 ng/μl, UCF DNA integrity analysis showed a sensitivity of 0.73 (95% CI 0.61–0.85), and a specificity of 0.84 (95% CI 0.71–0.97) in healthy individuals and 0.83 (95% CI 0.72–0.94) in symptomatic patients. Receiver operating characteristic (ROC) curve analysis revealed an area under the curve of 0.834 (95% CI 0.739–0.930) for healthy individuals and 0.796 (95% CI 0.707–0.885) for symptomatic patients. Conclusions These preliminary data suggest that UCF DNA integrity is a potentially good marker for early noninvasive diagnosis of bladder cancer. Its diagnostic performance does not seem to vary significantly, even in an “at risk” population of symptomatic individuals.</abstract><cop>United States</cop><pmid>23141783</pmid><doi>10.1016/j.urolonc.2012.07.013</doi><tpages>7</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1078-1439
ispartof Urologic oncology, 2013-11, Vol.31 (8), p.1744-1750
issn 1078-1439
1873-2496
language eng
recordid cdi_proquest_miscellaneous_1450194353
source MEDLINE; Elsevier ScienceDirect Journals Complete
subjects Aged
Biomarkers, Tumor - genetics
Biomarkers, Tumor - urine
DNA - genetics
DNA - urine
Early Detection of Cancer
Female
Humans
Male
Neoplasm Proteins - genetics
Proto-Oncogene Proteins c-myc - genetics
Real-Time Polymerase Chain Reaction
Receptor, ErbB-2 - genetics
Reference Values
ROC Curve
Spectrophotometry
Urinary Bladder Neoplasms - diagnosis
Urinary Bladder Neoplasms - genetics
Urinary Bladder Neoplasms - urine
Urology
title Urine Cell-Free DNA integrity as a marker for early bladder cancer diagnosis: Preliminary data
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-12T09%3A44%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Urine%20Cell-Free%20DNA%20integrity%20as%20a%20marker%20for%20early%20bladder%20cancer%20diagnosis:%20Preliminary%20data&rft.jtitle=Urologic%20oncology&rft.au=Casadio,%20Valentina,%20B.S&rft.date=2013-11-01&rft.volume=31&rft.issue=8&rft.spage=1744&rft.epage=1750&rft.pages=1744-1750&rft.issn=1078-1439&rft.eissn=1873-2496&rft_id=info:doi/10.1016/j.urolonc.2012.07.013&rft_dat=%3Cproquest_cross%3E1450194353%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1450194353&rft_id=info:pmid/23141783&rft_els_id=1_s2_0_S1078143912002554&rfr_iscdi=true